FDA has approved Darzalex (daratumumab) in combination with Velcade (bortezomib), a proteasome inhibitor; melphalan, an alkylating agent; and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
FDA approves Darzalex for newly diagnosed multiple myeloma patients who are transplant ineligible
YOU MAY BE INTERESTED IN
President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.” In his initial White House budget proposal—dubbed skinny budget, or budget-lite—Biden is requesting $6.5 billion to fund ARPA-H. “The discretionary request calls for $6.5 billion to...
Today Dr. Roswell Park is remembered mostly as the founder of the world’s first cancer research institute, which still bears his name proudly to this day in Buffalo, NY, but his contributions to medicine extend much further.